Email this article An acute experimental study to evaluate the effect of gatifloxacin on blood sugar levels in diabetic and non-diabetic rabbits
Abstract
Background: Diabetes mellitus is a condition characterized by chronic hyperglycemia and disturbance of carbohydrate, fat and protein metabolism associated with absolute or relative deficiencies in insulin secretion and/or insulin action. The objective of this study was to evaluate the effects of gatifloxacin on blood sugar levels in non-diabetic rabbits and alloxan induced diabetic rabbits.
Methods: Animals were fasted for 20 hours. Blood was collected for baseline investigations. After giving single oral dose of 2% gum acacia blood samples were drawn at 1, 2 and 4 hours for estimation of glucose and serum insulin. After 2 days a repeat blood sample for baseline was collected after 20 hours fasting and single oral dose of gatifloxacin 25 mg/kg was given. Samples of blood were taken at 1, 2 and 4 hours. After a wash out period of 7 days injection alloxan 140 mg/kg was given slowly intravenously to induce diabetes in the animals. On day 3 after alloxan induction, blood samples were taken from the animals (fasting 20 hours), for baseline investigations. Same procedure of blood collection and timing was followed as done before diabetes induction. The animals were given a single dose of gatifloxacin 25 mg/kg with blood samples drawn at 1, 2 and 4 hours for FBS and serum insulin.
Results: In non-diabetic rabbits, the effect of control and gatifloxacin on FBS levels at 1, 2 and 4 hours after administration was 100.3, 101.35, 102.89 mg/dl and 73.83, 73.04, 82.11 mg/dl respectively, on serum insulin levels at 2 hours interval was 3.62 and 4.16 μ IU/ml respectively. 48 hours after alloxan induction FBS and insulin levels were 219.13 and 1.19 μ IU/ml. After alloxan induction, FBS levels at 1, 2, 4 hours for control and gatifloxacin are 221.01, 224.13, 228 and 218.60, 218.53, 220.01 respectively. At 2 hours interval serum insulin levels were 1.15 and 1.21 μ IU/ml for control and gatifloxacin.
Conclusions: This study is in line with previous reports that gatifloxacin causes increased release of insulin leading to hypogycemia. The fall in blood sugar levels following a single oral dose of gatifloxacin is not limited to diabetic states alone and is more marked in non-diabetic rabbits.
Keywords
Full Text:
PDFReferences
Powers AC. Diabetes mellitus. In, Harrison’s Principles Of Internal Medicine, 16th edition, Braunwald E, Fauci AS, 2005;2:2152-62.
Emmerson AM. The quinolones: decades of development and use, Journal of Antimicrobial Chemotherapy. 2003;51(S1):13-20.
Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. New England Journal of Medicine. 2006;354(13):1352-61.
Onyenwenyi AJ, Winterstein AG, Hatton RC. An evaluation of the effects of gatifloxacin on glucose homeostasis. Pharmacy world and science. 2008;30(5):544-9.
Petri WA. Sulfonamides, trimethoprim- sulfamethoxazole, quinolones and agents for urinary tract infections. In, Goodman and Gilman’s, The Pharmacological Basis of Therapeutics; Laurence L. Brunton, John S. Lazo, Keith L. Parker, 11th edition, pa1; 2011:119-1122.
Myers B, Canada S. Health canada-endorsed important safety information on tequin (gatifloxacin). Available at www.hc-sc.gc.ca.
Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older patients. N Engl J Med. 2006;354:1352-61.
Ghosh MN. Toxicity Studies, In Fundamentals of Experimental Pharmacology, 3rd edition; 2007:192.
Ishiwata Y. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats, biological and pharmaceutical bulletin; 2006;29(3):527-31.
Tietz NW. In: Clinical guide to laboratory tests, W. B. Saunders Co. Philadelphia; 1976:238.
Nakagawa S, Nakayama H. A simple method for the determination of serum free insulin levels in insulin treated patients. Diabetes. 1973;22:590-600.
Gupta SK. Antidiabetic agents. In, Drug Screening Methods, 1st edition; 2004:306-329.
Davis SN. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In, Goodman and Gilman’s, The Pharmacological Basis of Therapeutics; Laurence L. Brunton, John S. Lazo, Keith L. Parker, 11th edition, 2006;1634-40.
Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugs. In, Basic and Clinical Pharmacology, 9th edition, Katzung BG. 2004;695-711.
Kendall C, Wooltorton E. People with diabetes should avoid antibiotic gatifloxacin. Canadian Medical Association Journal. 2006;174(8):1089-90.
Zvonar R. Gatifloxacin-induced Dysglycemia. American Journal of Health-System Pharmacy. 2006;63(21):2087-92.
Blommel AL. Severe hyperglycemia during renally adjusted gatifloxacin therapy. The Annals of Pharmacotherapy; 2005;1349-135.
Happe MR. Gatifloxacin- induced hyperglycemia, annals of internal Medicine. 2004;141(12):698-9.
Perry CM. Gatifloxacin, ADIS New Drug Profile, Drugs. 1999;58(4):683-96.
Ambrose PG. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. Journal of Antimicrobial Chemotherapy. 2003;52:435-40.
Westfall TC. Neurotransmission, drugs acting at synaptic and neuroeffector junctional sites. In, Goodman and Gilman’s, The Pharmacological Basis of Therapeutics; Laurence L. Brunton, John S. Lazo, Keith L. Parker, 11th edition; 2007;142-145.
Ganong WF. Endocrinology, metabolism and reproductive function, Ganong-Review of Medical Physiology 21st edition; 2010.
Maeda N. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. British Journal of Pharmacology. 1996;117(2):372-6.
Saraya A. Effects of fluoroquinolones on insulin secretion and β-cell ATP sensitive K+ channels. European Journal of Pharmacology 2004;497(1)111-7.
Yamada C. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. European Journal of Pharmacology. 2006;553(1-3):67-72.
